Life Sciences

Three months after being denied approval by the U.S. Food and Drug Administration, Cambridge-based Genzyme has won approval of its multiple sclerosis treatment in Brazil.

A Marlborough biotech company is reporting positive results from the second phase of a test for a drug intended to treat Type 2 diabetes. Theracos Inc. said the 96-week study, which involved 288 subjects with the disease from the U.S., Mexico and Colombia evaluated the effectiveness of its THR1442 drug, which is a sodium-glucose co-transporter 2, or SGLT2.

Life sciences education prospects are looking up with the latest wave of grants from the Massachusetts Life...

Marlborough-based Advanced Cell Technology announced Monday that it will restate financial results between 2009 and 2013 because it misapplied accounting guidance related to stock warrants issued in September 2005.

A Franklin laboratory that provides analytic testing and consulting services for clients in several industries will be moving operations to Milford this month after it signed a lease for space in a building once occupied by Thermo Fisher Scientific.

Gov. Deval Patrick on Thursday announced nearly $1 million in funding for life sciences-related capital projects at two area colleges.

Marlborough-based Oxford Immunotec narrowed its quarterly and yearly losses as revenue nearly doubled for the medical diagnostics firm, according to an earnings statement.

rEVO Biologics of Framingham will begin late-stage trials of a drug intended to prevent and treat hemophilia A and B bleeding episodes in patients who have developed resistance to other treatments methods.

Milford biotech startup Prothelia Inc. announced it has entered into an agreement with a Connecticut-based drug company to further develop Prothelia's clinical-stage treatment for the rare form of muscular dystrophy known as MCD1A. Alexion Pharmaceuticals Inc., which specializes in treatments for rare diseases, will have an option to acquire Prothelia and license its clinical-state treatment, Laminin-111, after entering into a “strategic agreement” with Prothelia and its research partner, the University of Nevada Reno (UNR), according to a statement from Prothelia.

Parcell Laboratories, a Natick-based provider of stem cell therapeutics, announced Wednesday that it's partnering with the University of Pittsburgh Medical Center (UPMC) to study a new stem cell-based wrinkle reduction treatment.